摘要
目的探究依折麦布联合辛伐他汀降脂治疗对冠状动脉粥样斑块进展和血脂水平的影响。方法回顾性分析2018年3月—2019年9月102例冠心病患者的临床资料。根据治疗方法不同将纳入患者分为联合组54例和对照组48例。联合组给予依折麦布联合辛伐他汀降脂治疗,对照组给予辛伐他汀降脂治疗。比较2组治疗前及治疗6个月后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、超敏C-反应蛋白(hs-CRP)、白介素-6(IL-6)、细胞凋亡抑制因子(sFas)、锌指Krüppel样转录因2(KLF2)水平,以及冠状动脉粥样斑块情况差异;并记录2组治疗期间不良反应发生情况。结果治疗后,2组TC、TG、LDL-C、hs-CRP、IL-6、sFas水平,以及冠状动脉血管体积、管腔体积、斑块体积均较治疗前降低,且联合组低于对照组(P<0.05)。治疗后,2组HDL-C、KLF2较治疗前升高,且联合组KLF2高于对照组(P<0.05),但2组间HDL-C比较差异无统计学意义(P>0.05)。2组治疗期间不良反应发生情况比较差异无统计学意义(P>0.05)。结论依折麦布联合辛伐他汀不仅能发挥良好的降脂作用,还能逆转冠心病患者冠状动脉粥样硬化进展,具有良好安全性。
Objective To explore the effects of Ezetimibe combined with Simvastatin lipid-lowering therapy on the progression of coronary atherosclerotic plaques and levels of blood lipids.Methods The clinical data of 102 patients with coronary heart disease(CHD)from March 2018 to September 2019 were retrospectively analyzed.According to different treatment methods,the included patients were divided into combination group(n=54)and control group(n=48).The combination group was given Ezetimibe combined with Simvastatin lipid-lowering therapy,and the control group was given Simvastatin lipid-lowering therapy.The total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6),inhibitor of apoptosis(sFas),zinc finger Krüppel-like transcription factor 2(KLF2)levels,and differences in coronary atherosclerotic plaque conditions were compared between the two groups before treatment and at 6 months after treatment.Occurrence of adverse reactions during treatment was recorded in the two groups.Results After treatment,the levels of TC,TG,LDL-C,hs-CRP,IL-6,sFas,and coronary vessel volume,lumen volume,plaque volume in the two groups were lower than those before treatment,which were lower in the combination group than in the control group(P<0.05).After treatment,HDL-C and KLF2 in the two groups were higher than those before treatment,and the KLF2 in the combination group was higher than that in the control group(P<0.05),but there was no significant difference in HDL-C between the two groups(P>0.05).There were no statistically significant differences in the occurrence of adverse reactions between the two groups during treatment(P>0.05).Conclusion Ezetimibe combined with Simvastatin can not only exert a good lipid-lowering effect,but also reverse the progression of coronary atherosclerosis in patients with coronary heart disease,and has good safety.
作者
王珺
柴玉琼
操兰平
孟晓瑜
WANG Jun;CHAI Yu-qiong;CAO Lan-ping;MENG Xiao-yu(Department of CCU of Cardiovascular Medicine,Central South Hospital of Wuhan University,Wuhan 430071,China;Department of Geriatrics,the Ninth Hospital of Xi'an,Xi'an 710054,China)
出处
《解放军医药杂志》
CAS
2020年第12期32-35,40,共5页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
湖北省卫生健康委科研基金(WJ2019H125)。
